Tarantino, Paolo http://orcid.org/0000-0001-8686-0228
Gupta, Hersh
Hughes, Melissa E.
Files, Janet
Strauss, Sarah
Kirkner, Gregory
Feeney, Anne-Marie
Li, Yvonne
Garrido-Castro, Ana C. http://orcid.org/0000-0002-5989-6636
Barroso-Sousa, Romualdo
Bychkovsky, Brittany L. http://orcid.org/0000-0001-7969-0603
DiLascio, Simona
Sholl, Lynette http://orcid.org/0000-0002-9532-9735
MacConaill, Laura
Lindeman, Neal
Johnson, Bruce E.
Meyerson, Matthew http://orcid.org/0000-0002-9133-8108
Jeselsohn, Rinath http://orcid.org/0000-0001-7996-7529
Qiu, Xintao http://orcid.org/0000-0002-8560-7017
Li, Rong http://orcid.org/0009-0000-1046-9580
Long, Henry http://orcid.org/0000-0001-6849-6629
Winer, Eric P.
Dillon, Deborah
Curigliano, Giuseppe http://orcid.org/0000-0003-1781-2518
Cherniack, Andrew D.
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Lin, Nancy U.
Funding for this research was provided by:
Fashion Footwear Association of New York
Breast Cancer Research Foundation
Article History
Received: 19 April 2023
Accepted: 7 November 2023
First Online: 18 November 2023
Change Date: 14 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-44124-y
Competing interests
: P.T. served as advisor/consultant for AstraZeneca, Daiichi-Sankyo, Gilead and Lilly. N.U.L. reports institutional research support from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, and AstraZeneca; consulting honoraria from Puma, Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, Blueprint Medicines, Stemline/Menarini, and Artera Inc. and Reverie Labs;.; and royalties from UptoDate (book). S.M.T. reports consulting or advisory roles for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi-Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Biopharma, Bayer, Incyte Corp, and Jazz Pharmaceuticals; and research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, and OncoPep. G.C. reports honoraria for speaker’s engagement from Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, NanoString, Samsung, Celltrion, BMS, MSD; honoraria for providing consultancy from Roche, Seattle Genetics, NanoString; honoraria for participating on the advisory boards of Roche, Lilly, Pfizer, Foundation Medicine, Samsung, Celltrion, Mylan; honoraria for writing engagement from Novartis and BMS; honoraria for participation in the Ellipsis Scientific Affairs Group; institutional research funding for conducting phase I and II clinical trials from Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck Serono, Merck Sharp Dome, Janssen-Cilag, Philogen, Bayer, Medivation, and Medimmune. A.C.G.-C. reports research funding (to Institution) from AstraZeneca, Daiichi-Sankyo, Merck, Gilead Sciences, Zenith Epigenetics; and travel accommodations from Roche/Genentech. R.B.-S. reports receiving speaker bureau fees from Agilant, AstraZeneca, Daiichi-Sankyo, Eli Lilly, Pfizer, Novartis, Merck, and Roche. He has also served as a consultant/advisor for AstraZeneca, Eli Lilly, Libbs, Roche, Merck and has received support for attending medical conferences from AstraZeneca, Roche, Eli Lilly, Daiichi-Sankyo, and Merck. D.D. has served as a consultant for Novartis, on the Advisory Board for Oncology Analytics and receives research funding from Canon Inc. B.E.J. reports that he has served as a paid consultant to Novartis, Checkpoint Therapeutics, Hummingbird Diagnostics, Daiichi- Sankyo, AstraZeneca, G1 Therapeutics, BlueDotBio, GSK, Hengrui Therapeutics, Simcere Pharmaceutical, Jazz Pharmaceuticals, and Merus N.V. He is also an unpaid member of a Steering Committee for Pfizer. He receives research support from Cannon Medical Imaging. A.D.C. receives research support from Bayer AG. M.M. reports research support from Bayer AG and Janssen; consulting for Bayer, Delve, Interline, and Isabl; and royalties from Bayer and LabCorp. R.J. reports research support from Pfizer and Lilly and serves as an advisor to GE Health and Carrick Therapeutics. The remaining authors declare no competing interests.